



Requisition #:	1012014	Practitioner:	ARAVINTHAN SUPPIAH
Patient Name:		Date of Collection:	12/14/2021
Patient Age:	19	Time of Collection:	Not Given
Patient Sex:	Μ	Print Date:	12/20/2021
Specimen Id.:	1012014-2		

$\left \right\rangle$
V V


Organic Acids Test - Nutritional and Metabolic Profile

Metabolic Markers in Urine	Reference Range (mmol/mol creatinine)	Patient Value	Reference Population - Males Age 13 and Over
Intestinal Microbial Overg	rowth		
Yeast and Fungal Markers			
1 Citramalic	0.11 - 2	2.0 0.57	0.5
2 5-Hydroxymethyl-2-furoic (Aspergillus)	<u> </u>	18 6.3	6.3
3 3-Oxoglutaric	≤ (0.11 0.04	0.0
4 Furan-2,5-dicarboxylic (Aspergillus)	≤ ŕ	13 3.4	34
5 Furancarbonylglycine (Aspergillus)	≤ 2	2.3 1.5	1.5
6 Tartaric (Aspergillus)	≤ ;	5.3 0.43	€ 43
7 Arabinose	≤ 2	20 19	19
8 Carboxycitric	≤ 2	20 0.18	0.18
9 Tricarballylic (Fusarium)	≤ (0.58 0.19	0.19
Bacterial Markers			
10 Hippuric	≤ 2	241 73	73
11 2-Hydroxyphenylacetic	0.03 - 0	0.47 0.20	0.2
12 4-Hydroxybenzoic	≤ (0.73 0.27	
13 4-Hydroxyhippuric	<u> </u>	14 2.2	2.2
14 DHPPA (Beneficial Bacteria)	≤ (0.23 0.03	
Clostridia Bacterial Markers			
15 4-Hydroxyphenylacetic (C. difficile, C. stricklandii, C. litusebur	ense & others) ≤ [∕]	18 6.9	6.9
16 HPHPA (C. sporogenes, C. caloritolerans, C. bo	otulinum & others) ≤ ´	102 13	13
17 4-Cresol (C. difficile)	≤ (39 5.2	5.2
18 3-Indoleacetic (C. stricklandii, C. lituseburense, C. su	≤ (bterminale & others)	6.8 1.2	12


Testing performed by The Great Plains Laboratory, LLC., Overland Park, Kansas. The Great Plains Laboratory has developed and determined the performance characteristics of this test. This test has not been evaluated by the U.S. FDA; the FDA does not currently regulate such

Requisition #:	1012014	Practitioner:	ARAVINTHAN SUPPIAH
Patient Name:		Date of Collection:	12/14/2021
Specimen Id.:	1012014-2		

Human Krebs Cycle showing Candida Krebs Cycle variant that causes excess Oxalate via Glyoxylate



Major pathways in the synthesis and breakdown of **catecholamine neurotransmitters** in the absence of microbial inhibitors



Organic Acids Test - Nutritional and Metabolic Profile Page 2 of 12

The Great Plains Labo	oratory, LLC		
Requisition #: 1012014			Practitioner: ARAVINTHAN SUPPIAH
Patient Name:			Date of Collection: 12/14/2021
Specimen Id.: 1012014	-2		
Metabolic Markers in Urine	Reference Range (mmol/mol creatinine)	Patient Value	Reference Population - Males Age 13 and Over
Oxalate Metabolites			
19 Glyceric	0.21 - 4.9	2.8	
20 Glycolic	18 - 81	H 110	
21 Oxalic	8.9 - 67	H 93	
Glycolytic Cycle Metabolites			93
22 Lactic	0.74 - 19	H 27	27
23 Pyruvic	0.28 - 6.7	H 7.8	
Mitochondrial Markers - Kre	bs Cycle Metabolites		
24 Succinic	≤ 5.3	1.6	
25 Fumaric	≤ 0.49	0.48	Q48>
26 Malic	≤ 1.1	0.87	
27 2-Oxoglutaric	≤ 18	H 26	
28 Aconitic	4.1 - 23	12	12
29 Citric	2.2 - 260	168	
Mitochondrial Markers - An	nino Acid Metabolites		
30 3-Methylglutaric	0.02 - 0.38	0.22	0.22
31 3-Hydroxyglutaric	≤ 4.6	H 5.6	5.6
32 3-Methylglutaconic	0.38 - 2.0	1.1	
Neurotransmitter Metabolite			
Phenylalanine and Tyrosine Metabol			
33 Homovanillic (HVA) (dopamine)	0.39 - 2.2	1.2	1.2
34 VanillyImandelic (VMA) (norepinephrine, epinephrine)	0.53 - 2.2	0.99	0.99
35 HVA / VMA Ratio	0.32 - 1.4	1.2	
36 Dihydroxyphenylacetic (DOPAC (dopamine)) 0.27 - 1.9	0.78	0.78
37 HVA/ DOPAC Ratio	0.17 - 1.6	1.5	
Tryptophan Metabolites			Ŷ
38 5-Hydroxyindoleacetic (5-HIAA) (serotonin)	≤ 2.9	1.1	
39 Quinolinic	0.52 - 2.4	2.4	2.4
40 Kynurenic	≤ 1.8	1.4	1.4

Organic Acids Test - Nutritional and Metabolic Profile Page 3 of 12

The Great Plains Laboratory, LLC

Metabolic Markers in Urine Reference Range (mmol/mol creatinine) Patient Value Reference Population - Males Age 13 and Over Pyrimidine Metabolites - Folate Metabolism 41 41 41 41 42 Thymine 5 6.9 2.6 42 Thymine 5 0.38 0.10 43 3.4hydroxybutyric 5 14 44 Acetoacetic 5 15 Ethylmalonic 0.13 2.7 1.7 46 Methylsuccinic 5 2.3 1.4 41 42 Acetoacetic 5 5 1.9 1.11 44 Acetoacetic 5 1.11 45 Methylsuccinic 5 2.12 1.11 47 Adipic 5 1.11 48 Suberic 5 1.11 49 Sebacic 5 1.11 49 Sebacic 5 1.11 49 Sebacic 5 2.12 11 12 12 13 14 15 <th>Patient Name:</th> <th>12014 2</th> <th></th> <th></th> <th>Practitioner: Date of Collection:</th> <th>ARAVINTHAN SUPPIAH 12/14/2021</th>	Patient Name:	12014 2			Practitioner: Date of Collection:	ARAVINTHAN SUPPIAH 12/14/2021	
41 Uracli \leq 6.9 2.6 42 Trymine \leq 0.36 0.10 Ketone and Fatty Acid Oxidation43 3-Hydroxybutyric \leq 1.9 H44 Acetoacetic \leq 10 8.5 45 Ethylmalonic 0.13 2.7 1.7 46 Methylsuccinic \leq 2.3 1.2 47 Adipic \leq 2.9 H48 Suberic \leq 1.9 H49 Sebacic \leq 0.14 0.07 Vitamin B1250 Methylmalonic \bullet \leq 2.3 51 Pyrdkoxic (B6) \leq 2.6 2.9 Vitamin B5 \leq 2.43 0.28 52 Pantothenic (B5) \leq 5.4 H74 Ascrobic 10 2.00 L 0.27 10 10 2.00 L 0.27 10 10 2.00 L 0.27 10 10 2.6 9.0 20 Vitamin C 5 5.13 0.05 53 Hydroxy-3-methylgutaric \bullet 5 0.13 0.05 10 10 2.00 10 10 53 Hydroxy-3-methylgutaric \bullet 5 0.13 0.05 10 10 2.00 10 10 10 10 2.6 9.0 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10		Reference Ra	-		Reference	ce Population - Males Age 13 and Over	
42 Thymine ≤ 0.36 0.10 Ketone and Fatty Acid Oxidation 43 3-Hydroxybutyric ≤ 1.9 H 14 44 Acetoacetic 5 10 8.5 45 Ethylmalonic 0.13 - 2.7 1.7 46 Methylsuccinic ≤ 2.3 1.2 42 47 Adipic ≤ 2.9 H 3.8 48 48 Suberic ≤ 1.9 H 13 49 49 Sebacic ≤ 0.14 0.07 400 Nutritional Markers Vitamin B12 50 5 2.6 2.9 20 51 Pyridoxic (B6) 5 2.6 2.9 20 400 Vitamin B2 51 Pyridoxic (B6) 5 2.6 2.9 20 400 Vitamin B2 52 Pantothenic (B5) 5 5.4 H 7.4 40 Vitamin C 54 Ascorbic 10 - 200 L 0.27 Vitamin C 5 3.0 5 5.4 400 55 3-Hydroxy 3-methylgutaric + 5 2.6 9.0 50 50 <td cols<="" th=""><th>Pyrimidine Metabolites</th><th>s - Folate Metabolisi</th><th>n</th><th></th><th></th><th></th></td>	<th>Pyrimidine Metabolites</th> <th>s - Folate Metabolisi</th> <th>n</th> <th></th> <th></th> <th></th>	Pyrimidine Metabolites	s - Folate Metabolisi	n			
Ketone and Fatty Acid Oxidation 43 3-Hydroxybutyric \leq 1.9 H 14 44 Acetoacetic \leq 10 8.5 $=$ 45 Ethyimalonic 0.13 \sim 7 1.7 46 Methylsuccinic \leq 2.3 1.2 $<$ $<$ 47 Adipic \leq 2.9 H 3.8 $<$ $<$ 48 Suberic \leq 1.9 H 13 $<$ $<$ 49 Sebacic \leq 0.14 0.07 $<$ $<$ $<$ Nutritional Markers Vitamin B12 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$	41 Uracil		≤ 6.9	2.6		2.6	
43 3-Hydroxybutyric ≤ 1.9 H 14 44 Acetoacetic ≤ 10 8.5 45 Ethylmalonic 0.13 $\cdot 2.7$ 1.7 46 Methylsuccinic ≤ 2.3 1.2 47 Adipic ≤ 2.9 H 3.8 48 Suberic ≤ 1.9 H 13 49 Sebacic ≤ 0.14 0.07 Nutritional Markers Vitamin B12 50 Methylmalonic \ast ≤ 2.3 1.8 Vitamin B6 51 Pyridoxic (B6) ≤ 26 2.9 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 7.4 Vitamin B5 53 Glutaric \ast ≤ 0.43 0.28 Vitamin C 53 Glutaric \ast ≤ 2.6 9.0 Vitamin C 54 Ascorbic 10 $\cdot 200$ L 0.27 Vitamin C 54 Ascorbic 10 $\cdot 200$ L 0.27 Vitamin C 54 Ascorbic 10 $\cdot 200$ L 0.27 Vitamin C 55 $\cdot 3$ -Hydroxy-3-methylglutaric \diamond ≤ 2.6 9.0 Q $\cdot 0$	42 Thymine		≤ 0.36	0.10		.10	
44 Acetoacetic \leq 108.545 Ethylmalonic0.13 \sim 2.7 1.7 46 Methylsuccinic \leq 2.3 1.2 47 Adipic \leq 2.3 1.2 48 Suberic \leq 2.9 H 3.848 Suberic \leq 0.14 0.07 49 Sebacic \leq 0.14 0.07 Nutritional Markers Vitamin B1250 Methylmalonic \bullet \leq 2.3 1.8 (18)Vitamin B5 \leq 2.4 H 7.4 $\langle 2.8 \rangle$ Vitamin B2 (Riboflavin) \leq 0.43 0.28 $\langle 2.9 \rangle$ <td>Ketone and Fatty Acid</td> <td>Oxidation</td> <td></td> <td></td> <td></td> <td></td>	Ketone and Fatty Acid	Oxidation					
45 Ethylmalonic $0.13 - 2.7 1.7$ 46 Methylsuccinic $\leq 2.3 1.2$ 47 Adipic ≤ 2.9 H 3.8 48 Suberic ≤ 1.9 H 13 49 Sebacic ≤ 0.14 0.07 <i>Nutritional Markers</i> Vitamin B12 50 Methylmalonic \ast ≤ 2.3 1.8 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 7.4 Vitamin B2 (Riboflavin) 53 Glutaric \ast ≤ 0.43 0.28 Vitamin C 54 Ascorbic 10 - 200 L 0.27 53 Hydroxy-3-methylglutaric \ast ≤ 2.6 9.0 Glutathione Precursor and Chelating Agent 56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 Biotin (Vitamin H)	43 3-Hydroxybutyric		≤ 1.9	H 14		<	
46Methylsuccinic \leq 2.3 1.2 47Adipic \leq 2.9 H 3.8 48Suberic \leq 1.9 H 13 49Sebacic \leq 0.14 0.07 Nutritional MarkersVitamin B1250Methylmalonic $*$ \leq 2.3 1.8 Vitamin B651Pyridoxic (B6) \leq 2.6 2.9 2.9 2.9 Vitamin B552Pantothenic (B5) \leq 5.4 H 7.4 Vitamin B2 (Riboflavin)53Glutaric $*$ \leq 0.43 0.28 0.43 0.28 0.43 0.28 0.13 0.05 0.13 0.05 0.13 0.05 0.13 0.05 0.13 0.05	44 Acetoacetic		≤ 10	8.5	· · · ·		
47 Adipic ≤ 2.9 H 3.8 48 Suberic ≤ 1.9 H 13 49 Sebacic ≤ 0.14 0.07 Nutritional Markers Vitamin B12 50 Methylmalonic \ast ≤ 2.3 1.8 Vitamin B6 51 Pyridoxic (B6) ≤ 26 2.9 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 7.4 Vitamin B2 (Riboflavin) 53 Glutaric \ast ≤ 0.43 0.28 Vitamin C 54 Ascorbic 10 - 200 L 0.27 Vitamin C 54 Ascorbic 10 - 200 L 0.27 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric \ast ≤ 26 9.0 Glutathione Precursor and Chelating Agent 56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 Biotin (Vitamin H)	45 Ethylmalonic	0.13	- 2.7	1.7		1.7	
48 Suberic ≤ 1.9 H 13 49 Sebacic ≤ 0.14 0.07 Nutritional Markers Vitamin B12 50 Methylmalonic \ast ≤ 2.3 1.8 Vitamin B6 51 Pyridoxic (B6) ≤ 26 2.9 23 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 7.4 Vitamin B2 (Riboflavin) 53 Glutaric \ast ≤ 0.43 0.28 Vitamin C 54 Ascorbic 10 - 200 L 0.27 27 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric \ast ≤ 26 9.0 Q12 Q12 Q13 Q14 Q15 Q15 Q15 Q15 Q15 Q15 Q15 Q15	46 Methylsuccinic		≤ 2.3	1.2		1.2	
49 Sebacic ≤ 0.14 0.07 Nutritional Markers Vitamin B12 50 Methylmalonic $*$ ≤ 2.3 1.8 Vitamin B6 51 Pyridoxic (B6) ≤ 26 2.9 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 7.4 Vitamin B2 (Riboflavin) 53 Glutaric $*$ ≤ 0.43 0.28 Vitamin C 54 Ascorbic 10 - 200 L 0.27 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric $*$ ≤ 26 9.0 Solution C Solutaric $*$ ≤ 26 9.0 Solutaric $*$ ≤ 26 ≈ 29 ≈ 20	47 Adipic		≤ 2.9	H 3.8		3.8>	
Nutritional Markers Vitamin B12 50 Methylmalonic $*$ \leq 2.3 1.8 50 Methylmalonic $*$ \leq 2.3 1.8 Vitamin B6 \leq 26 2.9 2 3 51 Pyridoxic (B6) \leq 26 2.9 2 3 Vitamin B5 \leq 5.4 H 7.4 Vitamin B2 (Riboflavin) \leq 0.43 0.28 0 225 Vitamin C \leq 0.43 0.27 0 27 54 Ascorbic 10 $-$ 200 L 0.27 Vitamin Q10 (CoQ10) \leq 26 9.0 \leq 9.0 \leq 0.13 0.05 Si Outathione Precursor and Chelating Agent \leq 0.13 0.05 0 \otimes 0 \otimes Biotin (Vitamin H) Elements of the first of the fir	48 Suberic		≤ 1.9	H 13		<	
Vitamin B12 50 Methylmalonic $*$ ≤ 2.3 1.8 50 Methylmalonic $*$ ≤ 2.3 1.8Vitamin B6 51 Pyridoxic (B6) ≤ 26 2.9 23 23 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 53 Glutaric $*$ ≤ 0.43 0.28 230 230 Vitamin C 54 Ascorbic 10 200 L 24 Ascorbic 10 200 L 0.27 27 230 230 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric $*$ ≤ 26 9.0 56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 200 Biotin (Vitamin H) 10 10 10 10	49 Sebacic		≤ 0.14	0.07		0.0	
50 Methylmalonic $*$ \leq 2.3 1.8 Vitamin B6 \leq 26 2.9 51 Pyridoxic (B6) \leq 26 2.9 Vitamin B5 \leq 5.4 H 52 Pantothenic (B5) \leq 5.4 H Vitamin B2 (Riboflavin) \leq 0.43 0.28 53 Glutaric $*$ \leq 0.43 0.28 Vitamin C 10 \sim 200 L 0.27 54 Ascorbic 10 \sim 200 L 0.27 Vitamin Q10 (CoQ10) \leq 26 9.0 9.0 55 3-Hydroxy-3-methylglutaric $*$ \leq 26 9.0 9.0 Glutathione Precursor and Chelating Agent \leq 0.13 0.05 0.05 Biotin (Vitamin H) $=$ 0.13 0.05 0.05	Nutritional Markers						
51 Pyridoxic (B6) ≤ 26 2.9 2.9 Vitamin B5 52 Pantothenic (B5) ≤ 5.4 H 7.4 Vitamin B2 (Riboflavin) 53 Glutaric $*$ ≤ 0.43 0.28 Vitamin C 54 Ascorbic 10 - 200 L 0.27 0.27 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric $*$ ≤ 26 9.0 Glutathione Precursor and Chelating Agent 56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 Biotin (Vitamin H)			≤ 2.3	1.8		1.8	
Vitamin B552 Pantothenic (B5) ≤ 5.4 H7.4Vitamin B2 (Riboflavin) ≤ 0.43 0.28 $\boxed{28}$ Vitamin C ≤ 0.43 0.28 $\boxed{28}$ Vitamin C 10 ~ 200 L 0.27 54 Ascorbic 10 ~ 200 L 0.27 Vitamin Q10 (CoQ10) ≤ 26 9.0 9.0 55 3-Hydroxy-3-methylglutaric * ≤ 26 9.0 9.0 Glutathione Precursor and Chelating Agent ≤ 0.13 0.05 $\bigcirc 0.5$ Biotin (Vitamin H) $= 0.13$ 0.05 $\bigcirc 0.5$					â		
52 Pantothenic (B5) \leq 5.4 H 7.4 Vitamin B2 (Riboflavin) \leq 0.43 0.28 $\bigcirc 28$ 53 Glutaric * \leq 0.43 0.28 $\bigcirc 28$ Vitamin C 10 \sim 200 L 0.27 54 Ascorbic 10 \sim 200 L 0.27 Vitamin Q10 (CoQ10) \leq 26 9.0 9.0 55 3-Hydroxy-3-methylglutaric * \leq 26 9.0 9.0 Glutathione Precursor and Chelating Agent \leq 0.13 0.05 $\bigcirc 0$ Biotin (Vitamin H) $=$ 0.13 0.05 $\bigcirc 0$			≤ 26	2.9	2.9		
53 Glutaric $*$ ≤ 0.43 0.28 Vitamin C 54 Ascorbic 10 - 200 L 0.27 0.2 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric $*$ ≤ 26 9.0 Glutathione Precursor and Chelating Agent 56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 Biotin (Vitamin H)			≤ 5.4	H 7.4		(7.4)	
54 Ascorbic 10 - 200 L 0.27 0.27 Vitamin Q10 (CoQ10) 55 3-Hydroxy-3-methylglutaric * \leq 26 9.0 9.0 Glutathione Precursor and Chelating Agent \leq 0.13 0.05 0.05 Biotin (Vitamin H) 0.05 0.05 0.05			≤ 0.43	0.28		0.28	
55 3-Hydroxy-3-methylglutaric * ≤ 26 9.0 9.0 Glutathione Precursor and Chelating Agent 56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 Biotin (Vitamin H) 56 0.05 0.05 0.05		10	- 200	L 0.27	0.27		
56 N-Acetylcysteine (NAC) ≤ 0.13 0.05 Biotin (Vitamin H)		ic *	≤ 26	9.0		9.0	
		elating Agent	≤ 0.13	0.05		0.05	
	Biotin (Vitamin H) 57 Methylcitric *	0.15	- 1.7	1.5	 	1.5	

* A high value for this marker may indicate a deficiency of this vitamin.

Organic Acids Test - Nutritional and Metabolic Profile Page 4 of 12

Requisition #: Patient Name: Specimen Id.:	1012014 1012014-2			Practitioner: Date of Collection:	ARAVINTHAN SUPPIAH 12/14/2021
Metabolic Markers in U	rine Reference F (mmol/mol cre	-	Patient Value	Reference Po	opulation - Males Age 13 and Over
Indicators of Detox	ification				
Glutathione 58 Pyroglutamic *	5.	.7 - 25	20		20
Methylation, Toxic expose 59 2-Hydroxybutyric * 4		≤ 1.2	H 2.2		<2.2>
Ammonia Excess 60 Orotic		≤ 0.46	0.22		0.22
Aspartame, salicylates, o 61 2-Hydroxyhippuric	r GI bacteria	≤ 0.86	0.18	0.18	

* A high value for this marker may indicate a Glutathione deficiency.

** High values may indicate methylation defects and/or toxic exposures.

Amino Acid Metabolites			
62 2-Hydroxyisovaleric	≤ 2.0	0.06	Ø.06
63 2-Oxoisovaleric	≤ 2.0	0	0.00
64 3-Methyl-2-oxovaleric	≤ 2.0	0.55	0.55
65 2-Hydroxyisocaproic	≤ 2.0	0	0.00
66 2-Oxoisocaproic	≤ 2.0	0.12	0.12
67 2-Oxo-4-methiolbutyric	≤ 2.0	0.27	0.27
68 Mandelic	≤ 2.0	0.03	
69 Phenyllactic	≤ 2.0	0.04	Q.04
70 Phenylpyruvic	≤ 2.0	1.4	
71 Homogentisic	≤ 2.0	0	
72 4-Hydroxyphenyllactic	≤ 2.0	0.21	
73 N-Acetylaspartic	≤ 38	2.5	2.5
74 Malonic	≤ 9.9	4.9	4.9
75 4-Hydroxybutyric	≤ 4.3	0	
Mineral Metabolism			
76 Phosphoric	1,000 - 4,900	2,437	243

Requisition #:	1012014	Practitioner:	ARAVINTHAN SUPPIAH
Patient Name:		Date of Collection:	12/14/2021
Specimen Id.:	1012014-2		
Indicator of Fluid Int	ake		

77 *Creatinine

185 mg/dL

*The creatinine test is performed to adjust metabolic marker results for differences in fluid intake. Urinary creatinine has limited diagnostic value due to variability as a result of recent fluid intake. Samples are rejected if creatinine is below 20 mg/dL unless the client requests results knowing of our rejection criteria.

Explanation of Report Format

The reference ranges for organic acids were established using samples collected from typical individuals of all ages with no known physiological or psychological disorders. The ranges were determined by calculating the mean and standard deviation (SD) and are defined as \pm 2SD of the mean. Reference ranges are age and gender specific, consisting of Male Adult (\geq 13 years), Female Adult (\geq 13 years), Male Child (<13 years), and Female Child (<13 years).


There are two types of graphical representations of patient values found in the new report format of both the standard Organic Acids Test and the Microbial Organic Acids Test.

The first graph will occur when the value of the patient is within the reference (normal) range, defined as the mean plus or minus two standard deviations.

The second graph will occur when the value of the patient exceeds the upper limit of normal. In such cases, the graphical reference range is "shrunk" so that the degree of abnormality can be appreciated at a glance. In this case, the lower limits of normal are not shown, only the upper limit of normal is shown.

In both cases, the value of the patient is given to the left of the graph and is repeated on the graph inside a diamond. If the value is within the normal range, the diamond will be outlined in black. If the value is high or low, the diamond will be outlined in red.


Example of Value Within Reference Range



Organic Acids Test - Nutritional and Metabolic Profile Page 6 of 12

Requisition #:	1012014	Practitioner:	ARAVINTHAN SUPPIAH
Patient Name:		Date of Collection:	12/14/2021
Specimen Id.:	1012014-2		

Neurotransmitter Metabolism Markers



The diagram contains the patient's test results for neurotransmitter metabolites and shows their relationship with key biochemical pathways within the axon terminal of nerve cells. The effect of microbial byproducts on the blockage of the conversion of dopamine to norepinephrine is also indicated.

Organic Acids Test - Nutritional and Metabolic Profile Page 7 of 12

Requisition #:	
Patient Name:	
Specimen Id.:	

1012014

1012014-2

Practitioner: Date of Collection: ARAVINTHAN SUPPIAH 12/14/2021

Interpretation

High glycolic (20): in the absence of oxalic is most likely a result of GI yeast overgrowth (Aspergillus, Penicillium, Candida) or due to dietary sources containing glycerol/glycerine. Glycolic acid had also been found to be a metabolite in Acetobacter, Acidithiobacillus, Alcanligenes, Corynebacterium, Cryptococcus, Escherichia, Gluconobacter, Kluyveromyces, Leptospirillum, Pichia, Rhodococcus, Rhodotorula and Saccharomyces (PMID: 11758919; PMID: 26360870; PMID: 14390024).

High oxalic (21) with or without elevated glyceric (19) or glycolic acids (20) may be associated with the genetic hyperoxalurias, autism, women with vulvar pain, fibromyalgia, and may also be due to high vitamin C intake. However, kidney stone formation from oxalic acid was not correlated with vitamin C intake in a very large study. Besides being present in varying concentrations in most vegetables and fruits, oxalates, the mineral conjugate base forms of oxalic acid, are also byproducts of molds such as *Aspergillus* and *Penicillium* and probably *Candida*. If yeast or fungal markers are elevated, antifungal therapy may reduce excess oxalates. High oxalates may cause anemia that is difficult to treat, skin ulcers, muscles pains, and heart abnormalities. Elevated oxalic acid is also the result of anti-freeze (ethylene glycol) poisoning. Oxalic acid is a toxic metabolite of trichloroacetic acid and other environmental pollutants. In addition, decomposing vitamin C may form oxalates during transport or storage.

Elevated oxalate values with a concomitant increase in glycolic acid may indicate genetic hyperoxaluria (type I), whereas increased glyceric acid may indicate a genetic hyperoxaluria (type II). Elevated oxalic acid with normal levels of glyceric or glycolic metabolites rules out a genetic cause for high oxalate. However, elevated oxalates may be due to a new genetic disorder, hyperoxaluria type III.

Regardless of its source, high oxalic acid may contribute to kidney stones and may also reduce ionized calcium. Oxalic acid absorption from the GI tract may be reduced by calcium citrate supplementation before meals. Vitamin B6, arginine, vitamin E, chondroitin sulfate, taurine, selenium, omega-3 fatty acids and/or N-acetyl glucosamine supplements may also reduce oxalates and/or their toxicity. Excessive fats in the diet may cause elevated oxalate if fatty acids are poorly absorbed because of bile salt deficiency. Unabsorbed free fatty acids bind calcium to form insoluble soaps, reducing calcium's ability to bind oxalate and increase its absorption. If taurine is low in a plasma amino acid profile, supplementation with taurine (1000 mg/day) may help stimulate bile salt production (taurocholic acid), leading to better fatty acid absorption and diminished oxalate absorption.

High levels of oxalates are common in autism. Malabsorption of fat and intestinal *Candida* overgrowth are probably the major causes for elevated oxalates in this disorder. Even individuals with elevated glyceric or glycolic acids may not have a genetic disease. To rule out genetic diseases in those people with abnormally high markers characteristic of the genetic diseases, do the following steps: (1) Follow the nutritional steps indicated in this interpretation for one month; (2) If *Candida* is present, treat *Candida* for at least one month; (3) Repeat the organic acid test after abstaining from vitamin C supplements for 48 hours; (4) If the biochemical markers characteristic of genetic oxalate disorders are still elevated in the repeat test, consider DNA tests for the most common mutations of oxalate metabolism. DNA testing for type I hyperoxaluria is available from the Mayo Clinic, Rochester, MN as test #89915 "*AGXT* Gene, Full Gene Analysis" and, for the p.Gly170Arg mutation only, as # 83643 "Alanine: Glyoxylate Aminotransferase [*AGXT*] Mutation Analysis [G170R], Blood"). Another option to confirm the genetic disease is a plasma oxalate test, also available from the Mayo Clinic (Phone 507.266.5700). Plasma oxalate values greater than 50 micromol/L are consistent with genetic oxalate diseases and may serve as an alternate confirmation test.

Organic Acids Test - Nutritional and Metabolic Profile Page 8 of 12

Requisition #:	1012014
Patient Name:	
Specimen Id.:	1012014-2

2014

Practitioner: Date of Collection: **ARAVINTHAN SUPPIAH** 12/14/2021

Specimen Id.:

Bone tends to be the major repository of excess oxalate in patients with primary hyperoxaluria. Bone oxalate levels are negligible in healthy subjects. Oxalate deposition in the skeleton tends to increase bone resorption and decrease osteoblast activity.

Oxalates may also be deposited in the kidneys, joints, eyes, muscles, blood vessels, brain, and heart and may contribute to muscle pain in fibromyalgia. Oxalate crystal formation in the eyes may be a source of severe eye pain in individuals with autism who may exhibit eye-poking behaviors. High oxalates in the GI tract also may significantly reduce absorption of essential minerals such as calcium, magnesium, zinc, and others. In addition, oxalate deposits in the breast have been associated with breast cancer.

A low oxalate diet may also be particularly useful in the reduction of body oxalates even if dysbiosis of GI flora is the major source of oxalates. Foods especially high in oxalates include spinach, beets, chocolate, soy, peanuts, wheat bran, tea, cashews, pecans, almonds, berries, and many others.

People with abnormally high markers characteristic of the genetic diseases should do the following:

- 1. Avoid spinach, soy, nuts, and berries for one month.
- 2. If Candida is present, treat Candida for at least one month.

3. Repeat the organic acid test having abstained from vitamin C supplements for 48 hours.

4. If the biochemical markers characteristic of genetic oxalate disorders are still elevated in the repeat test, consider DNA tests for the most common mutations of oxalate metabolism.

High lactic acid and/or high pyruvic acid (22,23) may be caused by many nonspecific factors, such as vigorous exercise, bacterial overgrowth of the GI tract, shock, poor perfusion, anemia, mitochondrial dysfunction or damage, and many other causes. Conversion of pyruvic acid to acetyl-CoA requires the cofactors coenzyme A (derived from pantothenic acid), lipoic acid, FAD derived from riboflavin, and thiamine. However, the possibility of an inborn error of metabolism increases as the value exceeds 300 mmol/mol creatinine. Values greater than 1000 mmol/mol creatinine indicate a much higher likelihood of an inborn error of metabolism. There are many inborn errors of metabolism that present elevated lactic acid, including disorders of sugar metabolism and pyruvate dehydrogenase deficiency.

High 2-oxoglutaric acid (alpha-ketoglutaric acid) (27) may be due to dietary deficiencies of any of several enzyme cofactors or the intake of alpha-ketoglutaric acid (AKG) as a supplement. Conversion of 2-oxoglutaric acid to succinyl-CoA requires the cofactors coenzyme A (derived from pantothenic acid), FAD (derived from riboflavin), and thiamine.* Increased conversion of glutamic acid to AKG is another possible explanation. Extremely high values (ten times the upper limit of normal) may be due to genetic enzyme deficiencies and indicate the need for consultation with a biochemical genetics specialist.

High 3-hydroxyglutaric (31) is a metabolite associated with the genetic disease glutaric aciduria type I, which is due to a deficiency of glutaryl CoA dehydrogenase, an enzyme involved in the breakdown of lysine, hydroxylysine, and tryptophan. Other organic acids elevated include glutaric and glutaconic. This disease has been associated with clinical symptoms ranging from near normal to encephalopathy, cerebral palsy, and other neurological abnormalities. Some individuals with glutaric acidemia have developed bleeding in the brain or eyes that may be mistaken for the effects of child abuse. This abnormality should be confirmed by additional testing of enzyme deficiencies and/or DNA at a major pediatric medical genetics center (Morton et al. Glutaric aciduria type I: a common cause of encephalopathy and spastic paralysis in the Amish of Lancaster County, Pennsylvania. American J. Med. Genetics 41: 89-95, 1991). Elevated values may also be found in hepatic carnitine palmitoyltransferase I deficiency, short-chain acyl dehydrogenase deficiency (SCAD), and ketosis. Mitochondrial dysfunction induced by glutaric acid metabolites causes astrocytes to adopt a proliferative phenotype, which may underlie neuronal loss, white matter abnormalities and macrocephalia. Values in glutaric aciduria type I range from 60-3000 mmol/mol creatinine. Values higher than normal but less than 60 mmol/mol creatinine may be due to mild glutaric acidemia type I or to the other causes indicated above. Treatment of this disorder includes special diets low in lysine and supplementation with carnitine or acetyl-L-carnitine.

Requisition #:	
Patient Name:	
Specimen Id ·	

1012014

1012014-2

Practitioner: Date of Collection: ARAVINTHAN SUPPIAH 12/14/2021

Homovanillic acid (HVA) levels (33) below the mean indicate low production and/or decreased metabolism of the neurotransmitter dopamine. Homovanillic acid is a metabolite of the neurotransmitter dopamine. Low production of HVA can be due to decreased intake or absorption of dopamine's precursor amino acids such as phenylalanine and/or tyrosine, decreased quantities of cofactors needed for biosynthesis of dopamine such as tetrahydrobiopterin and vitamin B6 coenzyme or decreased amounts of cofactors such as S-adenosylmethionine (Sam-e) needed to convert dopamine to HVA. In addition, a number of genetic variations such as single nucleotide polymorphisms (SNPs) or mutations can cause reduced production of HVA due to enzymes with decreased function. HVA values below the mean but which are much higher than VMA values are usually due to impairment of dopamine beta hydroxylase due to excessive Clostridia metabolites, the mold metabolite fusaric acid, pharmaceuticals such as disulfiram, or food additives like aspartame or deficiencies of cofactors such as vitamin C or copper. Values may also be decreased in patients on monoamine oxidase (MAO) inhibitors. In addition, a number of genetic variations such as single nucleotide polymorphisms (SNPs) or mutations in MAO or COMT genes can cause reduced production of HVA. Such SNPs are available on **The Great Plains DNA methylation pathway test** which can be performed on a cheek swab.

VanillyImandelic acid (VMA) levels (34) below the mean indicate low production and/or decreased metabolism of the neurotransmitters norepinephrine and epinephrine. VanillyImandelic acid is a metabolite of the neurotransmitters norepinephrine and epinephrine. Low production of VMA can be due to decreased intake or absorption of norepinephrine's and epinephrine's precursor amino acids such as phenylalanine and/or tyrosine, decreased quantities of cofactors needed for biosynthesis of norepinephrine and epinephrine such as tetrahydrobiopterin and vitamin B6 coenzyme or decreased amounts of cofactors such as S-adenosylmethionine (Sam-e) needed to convert norepinephrine and epinephrine to VMA. In addition, a number of genetic variations such as single nucleotide polymorphisms (SNPs) or mutations in MAO or COMT genes can cause reduced production of VMA. Such SNPs are available on The Great Plains DNA methylation pathway test which can be performed on a cheek swab. VMA values below the mean but which are much lower than HVA values are usually due to impairment of dopamine beta hydroxylase due to Clostridia metabolites, the mold metabolite fusaric acid, pharmaceuticals such as disulfiram, or food additives like aspartame or deficiencies of cofactors such as vitamin C or copper. Values may be decreased in patients on monoamine oxidase (MAO) inhibitors. Another cause for a low VMA value is a genetic variation (single nucleotide polymorphism or SNP) of the DBH enzyme. Patients with low VMA due to Clostridia metabolites or genetic DBH deficiency should not be supplemented with phenylalanine, tyrosine, or L-DOPA.

5-hydroxyindoleacetic acid (5HIAA) (38) levels below the mean may indicate lower production and/or decreased metabolism of the neurotransmitter serotonin. 5-hydroxy-indoleacetic acid is a metabolite of serotonin. Low values have been correlated with symptoms of depression. Low production of 5 HIAA can be due to decreased intake or absorption of serotonin's precursor amino acid tryptophan, decreased quantities of cofactors needed for biosynthesis of serotonin such as tetrahydrobiopterin and vitamin B6 coenzyme. In addition, a number of genetic variations such as single nucleotide polymorphisms (SNPs) or mutations can cause reduced production of 5HIAA. Such SNPs are available on **The Great Plains DNA methylation pathway test** which can be performed on a cheek swab. Values may be decreased in patients on monoamine oxidase (MAO) inhibitors that are drugs or foods that contain tyramine such such as Chianti wine and vermouth, fermented foods such as cheeses, fish, bean curd, sausage, bologna, pepperoni, sauerkraut, and salami.

High 3-hydroxybutyric acids (43) and/or acetoacetic acids (44) indicate increased metabolic utilization of fatty acids. These ketones are associated with diabetes mellitus, fasting, dieting (ketogenic or SCD diet), or illness such as nausea or flu, among many other causes.

High ethylmalonic, methylsuccinic, adipic, suberic, or sebacic acids (45,46,47,48,49) may be due to fatty acid oxidation disorders, carnitine deficiency, fasting, or to increased intake of the medium-chain triglycerides found in coconut oil, MCT oil, and some infant formulas. The fatty acid oxidation defects are associated with hypoglycemia, apnea episodes, lethargy, and coma. [An acyl carnitine profile (Duke University Biochemical Genetics Laboratory, http://medgenetics.pediatrics.duke.edu) can rule out fatty acid oxidation defects.] Regardless of cause, supplementation with L-carnitine or acetyl-L-carnitine may be beneficial.

Pyridoxic acid (B6) levels below the mean (51) may be associated with less than optimum health conditions (low intake, malabsorption, or dysbiosis). Supplementation with B6 or a multivitamin may be beneficial.

Organic Acids Test - Nutritional and Metabolic Profile Page 10 of 12

Requisition #:	1012014	Practitioner:	ARAVINTHAN SUPPIAH
Patient Name:		Date of Collection:	12/14/2021
Specimen Id.:	1012014-2		

High pantothenic acid (B5) (52) most commonly indicates recent intake of pantothenic acid as a supplement. Pantothenic acid is an essential B vitamin that is converted to coenzyme A (unrelated to vitamin A). Coenzyme A is needed for the synthesis of fatty acids, cholesterol, and acetyl choline and is also needed for the Krebs cycle and fatty acid catabolism. Because some individuals may require high doses of pantothenic acid, high values do not necessarily indicate the need to reduce pantothenic acid intake. However, if a patient who does not take B-vitamin supplements has high values of pantothenic acid, especially if the values are 20 or more times the upper limit of normal, the individual may have a genetic deficiency in the conversion of pantothenic acid to pantothenic acid-phosphate, which is the first step in the production of coenzyme A. It may be useful to retest after one week off all B-vitamin supplementation; individuals with PKAN would be expected to still have very elevated pantothenic acid levels even with no supplementation. This disease is called pantothenate kinase-associated neurodegeneration (PKAN), an inborn error of metabolism characterized by iron accumulation in the basal ganglia and by the presence of dystonia, dysarthria, Parkinson symptoms, and retinal degeneration. In mild variants of this disease, psychiatric illnesses such as schizoaffective disorder, hallucinations, obsessive compulsive disorder, speech defects, and depression are common. Mutations in pantothenate kinase 2 (PANK2), the rate-limiting enzyme in mitochondrial coenzyme A biosynthesis, represent the most common genetic cause of this disorder. Other biochemical abnormalities commonly found on the organic acid test in this disorder include elevated lactate, pyruvate, and Krebs cycle intermediates. Confirmation of mutant DNA requires special genetic testing. The University of Chicago does testing for PANK2 deletion for a price of \$1000 in 2017. The link is: <http://dnatesting.uchicago.edu/tests/pank2-deletionduplication-analysis>

Treatment for the illness is currently focused on giving high doses of pantothenic acid to stimulate any residual enzyme. Doses as high as 10 g per day have been ingested with few side effects. Other suggested therapies are increased supplementation with cholesterol, fat soluble vitamins, and bile salts. Since Lactobacillus species produce pantothenic acid phosphate, supplementation with high doses of probiotics might also be beneficial.

Ascorbic acid (vitamin C) levels below the mean (54) may indicate a less than optimum level of the antioxidant vitamin C. Individuals who consume large amounts of vitamin C can still have low values if the sample is taken 12 or more hours after intake. Supplementation with buffered vitamin C taken 2 or 3 times a day is suggested.

High 2-hydroxybutyric acid (59) This organic acid is elevated when there is increased production of sulfur amino acids derived from homocysteine. The reasons for an increase can be due to the following reasons (which are not mutually exclusive):

- 1. There is increased need for glutathione to detoxify a host of toxic chemicals, resulting in increased shunting of homocysteine into the production of cysteine for glutathione. This is the most common reason.
- 2. There are genetic variants of the DNA such that methylation of homocysteine by betaine homocysteine methyl transferase or methionine synthase is impaired. . SNPs of genes in the methylation cycle are available on **The Great Plains DNA methylation pathway test** which can be performed on a cheek swab.
- 3. There are nutritional deficiencies of betaine, methylcobalamin, or methyltetrahydrofolate that reduce the enzyme activities of the enzymes in #2 above.
- 4. There is a genetic variant in cystathionine beta synthase (CBS) enzyme such that there is excessive shunting of homocysteine into cysteine production that results in excessive 2-hydroxybutyric acid formation.
- 5. Onset of diabetes mellitus or excessive alcohol use.
- 6. Presence of certain genetic diseases such as lactic acidosis, glutaric aciduria type II, dihydrolipoyl dehydrogenase (E3) deficiency, and propionic aciduria.

High quality nutritional supplements can be purchased through your practitioner or at New Beginnings Nutritionals, <u>www.NBNUS.com <http://www.NBNUS.com></u>, or call 877-575-2467.

The nutritional recommendations in this test are not approved by the US FDA. Supplement recommendations are not intended to treat, cure, or prevent any disease and do not take the place of medical advice or treatment from a healthcare professional.

Organic Acids Test - Nutritional and Metabolic Profile Page 11 of 12

Requisition #:	1012014	Practitioner:	ARAVINTHAN SUPPIAH
Patient Name:		Date of Collection:	12/14/2021
Specimen Id.:	1012014-2		

Organic Acids Test - Nutritional and Metabolic Profile Page 12 of 12